PharmaGap Releases Compelling Results for Gap-107B8 From the U.S. National Cancer Institute
(EMAILWIRE.COM, August 25, 2009 ) OTTAWA, ONTARIO - PharmaGap Inc. (TSX VENTURE:GAP) (OTCBB:PHRGF) ("PharmaGap" or "the Company") is pleased to announce results from the initial testing of its lead cancer drug GAP-107B8 by the U.S. National Cancer Institute (NCI). The NCI data clearly demonstrates...more
PharmaGap Releases Results of Initial Testing For Novel Cancer Drug Compound at the Ottawa Hospital Research Institute
(EMAILWIRE.COM, August 07, 2009 ) Ottawa, Ontario – PharmaGap Inc. (TSX-V: GAP) ("PharmaGap" or "the Company") and the Ottawa Hospital Research Institute ("OHRI") today released initial testing results for PharmaGap’s cancer drug GAP-107B8 (formerly PhG-alpha-1). Led by Dr. Barbara Vanderhyden, OHRI...more
PharmaGap lead drug to be tested at the U.S. National Cancer Institute
(EMAILWIRE.COM, February 13, 2009 ) OTTAWA - PharmaGap Inc. (TSX-V: GAP) ("PharmaGap" or "the Company") today announced that, under the leadership of the Company's Clinical Development Group, the Company's lead drug compound PhG-alpha-1 has been accepted for testing at the National Cancer Institute...more
Private Equity, Angel Investing
Equity Alliance / Private Equity, Angel Investing, / IPO, Venture Capital & IR services / Equity Alliance International
Equityallianceir.com
Satellite TV for PC
Watch Streaming Tv Right on Your PC
Satellitetelevisionforpc.com
Your text Ads & PR
Text Ads plus unlimited press releases, One release featured/Day for only $575 per month.
Read more on Text Ads & PR
Your text Ads Here!
Text Ads are only $289 per month. Ads are placed same day.
More on Text Ads Advertising
Press Release
Resources
Benefits of Online Press Release Distribution Service
Press Releases
Press Release Examples
Press Release Format
Press Release Free
Press Release Service Comparison
Press Release Writing
Press release Writing Tips